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Abstract
Background: In breast cancer, the epithelial to mesenchyme transition (EMT) is associated to tumour
dissemination, drug resistance and high relapse risks. It is partly controlled by epigenetic modifications such as
histone acetylation and methylation. The identification of genes involved in these reversible modifications
represents an interesting therapeutic strategy to fight metastatic disease by inducing mesenchymal cell
differentiation to an epithelial phenotype.
Methods: We designed a siRNA library based on chromatin modification-related to functional domains and
screened it in the mesenchymal breast cancer cell line MDA-MB-231. The mesenchyme to epithelium transition
(MET) activation was studied by following human E-CADHERIN (E-CAD) induction, a specific MET marker, and cell
morphology. Candidate genes were validated by studying the expression of several differential marker genes and
their impact on cell migration.
Results: The screen led to the identification of 70 gene candidates among which some are described to be,
directly or indirectly, involved in EMT like ZEB1, G9a, SMAD5 and SMARCD3. We also identified the DOT1L as
involved in EMT regulation in MDA-MB-231. Moreover, for the first time, KAT5 gene was linked to the maintenance
of the mesenchymal phenotype.
Conclusions: A multi-parametric RNAi screening approach was developed to identify new EMT regulators such as
KAT5 in the triple negative breast cancer cell line MDA-MB-231.
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Background
In breast tumours, the epithelium to mesenchyme tran-
sition (EMT) is associated to early metastatic cell dis-
semination, drug resistance and high relapse risks [1].
During this epithelial cell dissemination, primary tu-
mours acquire a mesenchymal phenotype [2]. Cytoskel-
etal rearrangements resulting in loss of cell polarity and
morphology properties improve the migratory and inva-
sive features of the cells [3]. Relapse risks are frequent
for particularly aggressive cancer forms which display
EMT and invasive properties often associated to
CD44high / CD24-/low phenotype and present tumour ini-
tiating cell (TICs) features like auto-renewing and
chemo-resistance [4–6]. Interestingly, the analysis of
clinical samples indicates that metastases often closely
look like the primary tumour in morphology and gene
expression profile suggesting that the redifferentiation of
the metastasizing cell may occur via a mesenchymal to
epithelial transition (MET) [7]. Indeed, after MET, the
cells look and expand to form a secondary tumour [8–10].
Strikingly, changes in cellular characteristics during a bona
fide MET are to a large extent dependent on the upregula-
tion of E-CAD and the repression of N-CADHERIN (N-
CAD), both belonging to type-1 transmembrane proteins
class regulated by the MET program [3]. As cell dissemin-
ation and tumour initiation are linked to MET in breast
cancer, the identification of the targets involved in this
biological pathway is critical for the discovery of novel
therapies.
The role of epigenetic mechanisms in EMT of breast
cancer cells is emerging [11]. Epigenetic is composed of
chromatin modification (CM) such as DNA methylation,
histone post-modifications that dictates access to DNA,
thereby playing a major role in the regulation of tran-
scription, DNA recombination, replication, and repair
[12]. Higher-order chromatin structure is also an im-
portant regulator of gene expression during mammalian
development, lineage specification [13] and shapes the
mutational landscape of cancer [14]. Since chromatin
modifications are reversible, epigenetic marks constitute
ideal targets for therapeutic action.
Here, we aimed at identifying the regulators involved
in MET as future therapeutic targets in breast cancer.
MDA-MB-231 cell line was used as mesenchymal breast
cancer model and RNA interference (RNAi) was used to
identify the chromatin modifying domains involved in
MET. RNAi-mediated gene silencing is a valuable tool
widely used in drug discovery [15, 16] notably in high-
throughput screening [17, 18]. A set of 729 chromatin
modifying target genes were chosen according to the
bioinformatic study of Pu et al. [19] and pools of four
siRNA per target were designed.
Since E-CAD induction is a feature of MET, we
followed the detection of E-CAD by fluorescence
microscopy together with the change in cell morphology
towards an epithelial phenotype. To confirm the siRNA
hits, the expression of targeted genes and their impact
on cell migration were measured. Thereby, the already
described G9a, SMAD5 and SMARCD3 were identified
to be involved in MET, as also DOT1L that has been re-
cently published in this domain. Finally, for the first
time, KAT5 was found to be involved in MET.
Methods
Cell line and drug
MDA-MB-231 cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM-GlutaMAXTM-I from Gibco)
supplemented with 10 % fetal bovine serum (Lonza).
Cells were incubated at 37 °C with 5 % CO2 and subcul-
tured twice weekly during the experimental period.
EPZ-5676 was purchased from ChemScene (USA). A
DMSO stock solution (10 mM) was prepared and stored
at −20 °C until ready for use. Working dilutions were
prepared in DMEM just before use.
SiRNA and miRNAs
The SMARTpool siRNA library (targeting 729 known
and putative human chromatin modifiying genes) was
purchased from Dharmacon (GE Healthcare) in ten 96-
well plates (80 SMARTpool siRNAs/plate). The ON-
TARGETplus siRNA SMARTpool against ZEB1 was
purchased from Dharmacon (GE Healthcare) whereas
the negative control siRNA (siScr) was purchased from
Qiagen (AllStars Negative Control). The pre-miR-200a,
pre-miR-200c and pre-miR Negative Control 2 were pur-
chased from Ambion (Life Technologies) [20].
siRNA screening and hits validation
MDA-MB-231 (3,000/well) were reverse transfected in
96-well plates, in duplicate, with SMARTpool siRNA li-
brary using Lipofectamine® RNAiMAX (Invitrogen) fol-
lowing the manufacturer’s instructions. The final
concentration of each SMARTpool siRNA was 10nM in
100 μl medium per well. After 72 h, media were removed
and cells were re-transfected (forward transfection) with
SMARTpool siRNA at the same concentration as previ-
ously described. After 72 h, media were definitively re-
moved and cells were washed one time with PBS1x before
fixation with 3.7 % paraformaldehyde (Sigma-Aldrich) and
permeabilization with 0.1 % Triton X-100 (Sigma-Al-
drich). The plates were then blocked with PBS1x contain-
ing 2 % BSA plus 0.05 % Tween-20 (Sigma-Aldrich)
overnight at 4 °C. Next, the plates were incubated with
mouse anti-E-CAD antibody (1:200; BD Pharmingen) for
2 h at room temperature. After washing three times with
PBS 1× plus 0,05 % Tween 20, the plates were incubated
with a mixture of Alexa Fluor® 488 Donkey Anti-Mouse
antibody (1:1000; Life Technologies), Texas-Red®-X
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Phalloidin (1:200; Life Technologies) and DAPI (1:2000;
AAT Bioquest) for 1 h at room temperature, washed three
times before analysis on the IN Cell Analyser 1000 (20×,
GE Healthcare). Five fields per well were scanned and ana-
lysed. Each plate contained two positive controls (a
SMART pool directed against ZEB1 and a pre-miR200c)
and two negative controls (cells treated with transfection
reagent alone; and transfected with a scramble siRNA).
For each transfection, the immunofluorescence of E-CAD
was normalized to the cell number measured by DAPI
staining. The data were normalized to the median signal
of the plate and MAD (median absolute deviation) was
used for hit selection [21]. For analysis, since the values
measured for the ZEB1 positive control were between one
or two MAD, hits were selected on this criteria: a MAD
value superior to one. The MAD value was associated to
cell morphological change analysis (Moreno-Bueno et al.
[22]). For hit validation, E-CAD induction was measured
by RT-qPCR and considered positive if two single siRNA
out of the four of the pool were positive (Boutros et al.
[23]). The significance of E-CAD induction was analysed
using the Wilcoxon-Mann-Whitney test. A p-value <0.05
was considered statistically significant.
RNA isolation
After two successive transfections, cells were harvested
by trypsinization and total RNA was isolated using the
RNeasy plus mini kit following the manufacturer’s in-
structions (Qiagen). The quantity and quality of the
RNA were determined using the NanoDrop 2000 spec-
trophotometer (ThermoScientific).
Quantitative RT-qPCR
cDNA was synthetized from 1 μg of total RNA using the
SuperScript® VILOTM cDNA Synthesis Kit according to
the manufacturer’s instructions (Life Technologies).
QRT-PCR was performed using SYBR® Green PCR
Master Mix (Applied Biosystem) and a CFX384TM Real-
Time PCR Detection System (Bio-Rad). Gene expression
was normalized to three endogenous control genes (hydro-
xymethylbilane synthase (HMBS), Peptidylprolyl Isomerase
A (PPIA), Importin 8 (IPO8).
PCR primers were synthetized by Eurogentec. The fol-
lowing primer sequences were used.
For DOT1L, 5’-GCTGCCACCAGACTGACCA-3’(for-
ward) and 5’-TCCTAGTTACCTCCAACTGTGCC-3’(re-
verse); for KAT5 5’-TCCCCAGGGGGAGATAATCGAG-
3’(forward) and 5’-GCCAGGGGCCACTCATCTTC-3’
(reverse); for E-cadherin 5’-TCCCACCACGTACAAGG
GTC-3’(forward) and 5’-GGGGGCATCAGCATCAGTC
A-3’(reverse); for CD24 5’-AACTAATGCCACCACCAA
GG-3’(forward) and 5’-GACGTTTCTTGGCCTGAGTC-
3’(reverse); for TSPAN13 QuantiTect Primer Assay (Qia-
gen); for HMBS 5’-ATACAGACGGACAGTGTGGTGG
C-3’(forward) and 5’-CCCTGTGGTGGACATAGCAATG
A-3’(reverse); for PPIA 5’-GAGCACTGGAGAGAAAG
GATTTGGTT-3’(forward) and 5’-CGTGTGAAGT CAC




Migration assays were performed with the OrisTM Cell
Migration Assay following the manufacturer’s instruc-
tions (PLATYPUS Technologies). Briefly, after two
successive transfections, cells were harvested by trypsini-
zation and counted. For each transfection, 80.000 cells/
well were seeded and allowed to adhere for 24 h. Stoppers
were removed and the plate was incubated to permit cell
migration for 24 h. The cells were labelled with calcein
AM (Life Technologies) and the fluorescence was detected
using a Typhoon Trio (GE-Healthcare). The effects on cell
migration were estimated by cell surface area calculation
using Image J program (National Institutes of Health
Image). Each experiment was done in triplicate with two
independent repeats.
Results and discussion
Design of the 729 siRNA pool library
The siRNA pool library is directed against 729 known or
predicted chromatin modifier genes like chromatin-
remodeling factors (KATs, HDACs, KMTs and KDMs),
transcriptional coactivators or corepressors (Additional
file 1). Substantial evidences show that the chromatin
modifying factors exhibits distinct protein domains that
perform specific functions, such as SET domain (a cata-
lytic domain of many histone lysine methyl-transferases),
Bromodomain (responsible for recognition of acetylated
histone lysine) or Chromodomain (responsible for bind-
ing of methylated histone lysine) [24–26]. The library,
which includes four independent siRNAs for each tar-
geted gene, was designed according to an orthology-
based computation analysis of the Pfam protein database
looking for the protein domains involved in chromatin
modification [19, 24–27]. In this study, the authors pre-
dicted 397 novels CM genes (coding for 329 proteins) in
humans in addition to 398 experimentally verified ones
to propose a library of genes in chromatin modification.
Here, the siRNA library was generated by deleting unval-
idated gene sequences and adding genes involved in
DNA methylation to obtain the 729 siRNA pools library
(Additional file 1 for the list of the RNAi bank).
Screening strategy’s steps
To identify new chromatin modifying genes involved in
the maintenance of the mesenchymal state, a four step
strategy was performed (Fig. 1). The triple-negative
breast cancer (TNBC) cell line model MDA-MB-231
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was chosen because it’s representative of the
mesenchymal-like phenotype of cancer cells and rep-
resents one of the most aggressive human cancer cells
when grafted in mice [28, 29]. Interestingly, HDACi
inhibition initiates a partial MET which is associated
to decreased tumorigenesis in vivo [30] indicating that
by acting on the epigenetic regulation it is possible to
reverse the mesenchymal phenotype. In addition, this
cell line has a relatively high percentage of CD44
+/CD24-/low cells which have been reported to have
stem/progenitor cells properties [4] and enhanced in-
vasive properties [31].
The MDA-MB-231 cells do not express, or weakly, E-
CAD which is silenced by methylation of its promoter
[28]. The MET is partly characterized by the reactivation
of E-CAD a marker of the epithelial state. Thus, the first
step of the strategy consisted in screening the 729 siRNA
pools on these cells to identify the pools of siRNA that
induced E-CAD as followed by immunofluorescence. In
parallel, epithelial cell morphology was followed by
F-ACTIN immunofluorescence staining. Second, the 4
siRNA of each active pool were tested separately on both
E-CAD induction and cell morphology. Third, the
down-regulation of the targeted genes was confirmed by
RT-qPCR. Fourth, the effect of the siRNA was further
validated by inhibition of the migration properties of the
cells.
Cell-based assay validation
The microRNA-200 (miR-200) family has emerged re-
cently as important regulators of EMT/MET [32].
This family comprises five members expressed from
two distinct polycistronic transcripts (miR-200b ~
200a ~ 429 and miR-200c ~ 141) and, on the basis of
their ‘seed’ sequence [33], can be separated in two
functional groups (miR-200b/200c/429 and miR-141/
200a). The miR-200c is known to be involved in cells
undergoing EMT/MET [20, 34].
The miR-200c and a miRNA negative control were
used as positive and negative controls respectively. The
comparison of miR-200c and miRNA negative control
transfected cells in phase contrast microscopy showed a
dramatic change of cell morphology, from an elongated
fibroblast-like shape with pronounced cellular scattering
to a cobblestone-like epithelial phenotype (Fig. 2a). RT-
qPCR analysis revealed a significant increase in the ex-
pression of the epithelial marker E-CAD mRNA in
miR200 family (miR-200b and miR200a) transfected cells
(Fig. 2b). The immunofluorescence analysis of E-CAD
reinforced this result. In several cancer cell types, the
miR-200 family is able to enforce an epithelial state by
inhibiting the E-CAD transcriptional repressor ZEB1
[33, 35]. In our model, cells transfected with miR-200c,
or a specific SMARTpool directed against ZEB1, showed
a strong E-CAD cellular membrane staining and a
discrete nuclear staining whereas MDA-MB-231 cells
transfected with a miRNA negative control (data not
shown) or an irrelevant siRNA only showed a weak nu-
clear staining (Fig. 2c). As E-CAD nuclear staining was
unexpected, we conducted the same experiment with a
second antibody directed against E-CAD obtaining the
same result (data not shown). Finally, we observed an in-
crease in E-CAD signal and F-ACTIN staining with
phalloidin clearly revealed the cuboidal phenotype, typ-
ical of epithelial cells, of miR-200c and siZEB1 trans-
fected cells (Fig. 2c). Taken together, these experiments
validate miR-200c and siZEB1 as inducers of MET in
MDA-MB-231 cells.
siRNA screening reveals genes potentially involved in
MET
Transfection reagent, cell number and siRNA concentra-
tions were optimized to obtain a maximum of 20 % re-
duction in cells viability when transfected with the
irrelevant (non silencing) siRNA compared to mock-
E-CAD induction and/or epithelial 
morphology phenotype on 729 siRNA pools : 
70 siRNA active on phenotypes
 E-CAD induction and cell-morphology
on separated siRNA from active pools
mRNA expression level analysis of targeted genes
after siRNA gene silencing
Migration properties of MDA-MB-231 cells 





Fig. 1 Screening strategy. A four step process was used to identify
MET inducer gene candidates. a The primary screening was performed
on 729 siRNA pools targeting 729 genes selected for chromatin
structure maintenance. From E-CAD induction measurements and cell
morphology observations, 70 pools were identified. b Deconvolution
analysis: E-CAD induction and cell morphology were analysed for each
siRNA contained in the active pools. c Transcript quantification was
done by RT-qPCR to control gene knockdown. d Cell migration study:
the lost of the mesenchyme phenotype was associated to impaired
migration capabilities for several siRNA
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transfected (cells treated with transfection reagent, no
siRNA) and untransfected cells. Screening conditions
were also optimized to ensure high transfection effi-
ciency by using a siRNA pool targeting the essential
gene, KIF11 (EG5) (data not shown).
To calculate E-CAD induction in the screen, a statis-
tical method based on MAD calculation was used [21].
This method enabled a significant E-CAD induction de-
tection of miR-200c and siZEB1 transfected cells. The
MAD calculation method identified two groups of hit
SMART pools. Group A contains 53 genes whose indi-
vidual knockdown induced a statistically significant in-
crease in E-CAD cellular fluorescence (threshold ≥ one
MAD) and morphological changes associated to a partial
reversal of the mesenchymal phenotype and group B tar-
geting 17 genes, which knockdown induced only mor-
phological changes. Due to cell and siRNA transfection
heterogeneity, we also considered these genes because
they might be associated with modifications of adhesion
properties and linked to metastatic process.
Hit validation
The fact that several target genes were already known to
be involved, directly or indirectly, in MET conforted our
strategy. These genes include in particular G9a [36],
SMARCD3 [37], SMAD5 [38] and ZEB1, which is also the
positive control (Fig. 3) [39]. We then focused on two
genes: DOT1L (group B) and KAT5 (Tip60) (group A)
(Fig. 4a and 5a). DOT1L is a histone H3 lysine 79 methyl-
transferase whose inhibition increases the yield of induced
pluripotent stem cells (iPSCs) [40]. It was described very
recently as an EMT modulator through a bioinformatic
analysis of a large breast cancer genetic database [41].
KAT5 is an histone acetyltransferase (HAT) required to
maintain characteristic features of ESCs [42]. It is linked




































Fig. 2 Cell based assay development and validation. a MDA-MB231 cells were transfected with a pre-miRNA negative control (ctrl; 5nM)
or pre-miR-200c (5nM). Phase contrast images were taken at 6 days after 2 successive transfections (magnification, ×10). b MDA-MB-231
cells were transfected as in A with a pre-miR negative control scramble (ctrl), pre-miR-200a (200a), pre-miR-200c, mix of pre-miR200a +
pre-miR-200c (200a/c) (10 nM) and after 6 days the expression of E-CAD and GAPDH were studied by RT-qPCR. Non treated cells (NT);
Mock-transfected cells (Mock). c Immunofluorescence staining of E-CAD (green) and texas-red phalloidin staining of F-ACTIN (red) in cells
transfected as in (a) with scramble (siScr), pre-miR-200c and a ZEB1-specific siRNA pool (10 nM). Cells are counterstained with DAPI (blue)
to visualize nuclei. Scale bars, 100 μm
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To confirm the initial results and eliminate false posi-
tives due to off-target effects, we repeated the primary
screen using deconvoluted single siRNAs targeting
DOT1L and KAT5 (Figs. 4b and 5b). For each target,
two out of four siRNAs tested present in the pools
reproduced the observed primary screen phenotypes.
Most remarkably, two out of four siRNAs targeting
DOT1L were found to be significant E-CAD inducers
when tested individually placing the DOT1L also in
group A (Fig. 4b). The difference between the SMART
pool and the single siRNA could be due to the siRNA
potency. The effect of the DOT1L and KAT5 knockdown
was further demonstrated by RT-qPCR and correlated to
an increase in E-CAD mRNA and to a decrease in
DOT1L or KAT5 mRNA levels. The implication of the
two genes in MET regulation and stem/progenitor cell
phenotypes was investigated by following the expression
of mesenchymal and epithelial marker genes such as
vimentin, ZEB1, E-cadherin, Tetraspanin 13 (TSPAN13),
Occludin (OCLN) and the stem/progenitor cell surface
markers CD24 and CD44. Among the seven markers
studied, changes in E-CAD and CD24 expression were
observed in response to DOT1L silencing and in E-CAD
and TSPAN13, a potent breast cancer suppressor gene
[43], after KAT5 knockdown (Fig. 5c). The different
marker expression profiles observed after DOT1L or
KAT5 silencing may reflect partial MET [44].
A functional change associated with EMT is an in-
crease in migration and/or invasion capacities [45]. As
DOT1L or KAT5 silencing strongly decreases migration
of MDA-MB-231, in vitro, after two successive transfec-
tions with no major effect on cell viability (Fig. 5d), we
argued that DOT1L and KAT5 were involved in differ-
ent steps of MDA-MB-231 differentiation and could be
potential therapeutic targets to inhibit TNBC metastasis.
Finally, to confirm DOT1L as therapeutic target, we
treated MDA-MB-231 cells with a potent and selective












































































Fig. 3 High throughput functional screen to detect genes potentially involved in MET. a Four examples obtained in the initial screen. E-CAD
expression was normalized to cell number then data were normalized to the median of SMARTpools in the same plate (n = 80 SMARTpools/plate).
Threshold and hits selection were based on MAD calculation. b Morphological changes are revealed by F-ACTIN staining (red) as described before.
Scale bars, 100 μm
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treatment, this drug showed a strong dose-dependent in-
crease in E-CAD mRNA and a slight upregulation of
CD24 mRNA (Fig. 6). These results were totally consist-
ent with gene expression changes observed after DOT1L
silencing and confirmed the role of DOT1L in MDA-
MB-231 CSC-like cells differentiation.
Conclusions
From this RNAi-based phenotypic screening, we have
identified a set of 70 potentials hits, that may promote
the conversion of the highly invasive mesenchymal-like
cells MDA-MB-231 into a more differentiated and less
aggressive phenotype. KAT5 and DOT1L gene downreg-
ulation induced E-CAD expression and epithelial mor-
phological changes. The process was validated by the
finding of hits such as ZEB1, G9a, SMAD5, SMARCD3,
already reported in the literature to be implicated in the
regulation of EMT/MET. Indeed, ZEB1 is a well known
transcriptional repressor directly implicated in the con-






















































































































Fig. 4 DOT1L silencing induces MET and CD24 mRNA expression in MDA-MB-231 in vitro. a Quantitative and qualitative analysis after transfection with
DOT1L SMARTpool. b Quantitative and qualitative analysis after transfection with four individual siRNA and the DOT1L SMARTpool in MDA-MB-231
cells. Individual siRNAs significantly induced E-CAD (siRNA 1, 2) and morphological changes (siRNA 2) compared with siScr transfected cells. Data are
presented as the mean ± sd of 2 independent experiments each with 3 biological replicates (* p < 0.05, **p < 0.01, ***p < 0.001 compared with siScr
determined by Wilcoxon-Mann Whitney’s test). c RT-qPCR quantification of DOT1L, E-CAD and CD24 transcripts using specific primers in MDA-MB-231
cells transfected with individual siRNA 1 (10 nM) and 2 (0.1 nM). The columns represent the mean expression ± sd of 2 independent experiments
normalized to siScr. d Individual siRNA 1 (10 nM) reduced the migration compared with siScr or miR-200c transfected cells. Data are presented as the
mean ± sd of 2 independent experiments each with 2 biological replicates. Scale bars, 100 μm
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design the screening assay. The knock-down of G9a, a
histone methyltransferase, restored E-CAD expression,
caused morphological changes and attenuated migratory
and invasive capacity of MDA-MB-231 cell line in vitro
and in vivo [36]. Furthermore, SMAD5 phosphorylation
induced by an aberrant Aurora-A kinase activity, led to
its nuclear activation and ultimately contributed to the de-
velopment of EMT, stemness and tumor progression in
human breast cancer cell line MCF-7 [38]. Finally,
the silencing of SMARCD3/Baf60c, a SWI/SNF
chromatin-remodeling factor, gives a strong MET by
Wnt5a downregulation in EpCAM- SUM149 or SUM229
subpopulation [37].
Among the 70 gene candidate as putative MET regula-
tors, DOT1L and KAT5 were found to both induce E-



















































































































Fig. 5 KAT5 silencing induces MET and TSPAN13 mRNA expression in MDA-MB-231 in vitro. a Quantitative and qualitative analysis after transfection
with KAT5 SMARTpool of E-CAD induction and cell morphology. b Quantitative and qualitative analysis after transfection with four individual siRNA
and the KAT5 SMARTpool in MDA-MB-231 cells. Data are presented as the mean ± sd of 2 independent experiments each with 3 biological replicates
(* p < 0.05, **p < 0.01, ***p < 0.001 compared with siScr determined by Wilcoxon-Mann Whitney’s test). c RT-qPCR quantification of KAT5, E-CAD and
TSPAN13 transcripts using specific primers in MDA-MB231 cells transfected with individual siRNA 1 (10nM) and 2 (1nM). The columns represent the
mean expression ± sd of 2 independent experiments normalized to siScr. d Individual siRNA 1 (10nM) reduced the migration compared with siScr or
miR-200c transfected cells. Data are presented as the mean ± sd of 2 independent experiments each with 2 biological replicates. Scale bars, 100 μm
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phenotype in MDA-MB-231. DOT1L was previously
identified as a modulator of pluripotent stem cells
(iPSCs) reprogramming [40] and shown to methylated
the H3K79 mark which is critical in Mixed Lineage
leukemia (MLL) by enhancing expression of
leukemogenic genes like HOXA9 and MEIS1 [47]. In
vivo, administration of a DOT1L selective inhibitor
increased the lifespan of mice grafted with a preclin-
ical model of MLL [46]. In colon cancer, DOT1L in-
creases cancer stemness and tumorigenic potential by
inducing the core stem cell genes NANOG, SOX2 and
Pou5F1 [48]. In this study, DOT1L silencing and
chemical inhibition by EPZ5676 induced E-CAD and
CD24 expression and reduced the migration proper-
ties of MDA-MB-231 cells. These results support the
idea that DOT1L is involved in EMT and in the
maintenance of CD44+/CD24- cancer stem cells
present in MDA-MB-231 cell line. These results are
in agreement with those published by Zhang et al. in
2014, showing that DOT1L was a potential drug tar-
get for breast cancer and metastatic disease [41].
Finally, this siRNA screening led to the identifica-
tion of KAT5, a target never described in MET regu-
lation up today. KAT5 is a HAT with regulatory
functions in signalling, transcriptional activation,
DNA repair, apoptosis and cell cycle progression [49].
In embryonic stem cells (ESCs), one of the most im-
portant functions of KAT5 is to repress developmen-
tal genes [42]. In basal-like breast cancer, the TWIST
protein, a well known EMT inducer [50], is
specifically diacetylated by KAT5 to interact with
BRD4 and activate WNT5A. As a result of this inter-
action, it induces invasion and increases (CSC)-like
properties and tumorigenicity. Lastly, in radioresistant
subpopulations of breast cancer cells induced by ir-
radiation, ATM, a protein activated by KAT5 acetyl-
ation, is hyperactivated and mediates stabilization of
ZEB1, another well known EMT inducer, in breast
cancer and other types of solid tumours [51, 52].
Altogether, combined with the fact that KAT5 silen-
cing induces E-CAD and TSPAN13 expression, it
strongly suggests that a KAT5 inhibitor can induce
TNBC differentiation (basal-like subtype) and, in
combination with classical chemotherapeutic agents,
reduces the number of metastases [53]. Another study
shows a metastatic suppression function of KAT5 in a
prostate cancer model highlighting the fact that EMT
regulation is strongly tissue dependant [54]. Moreover,
as a result of the direct relationship between KAT5
and ATM kinase, our findings may highlight the crit-
ical role of the DNA damage response (DDR) in
tumorigenesis and metastasis in the basal subtype of
breast cancer [55, 56].
In conclusion, the screening method we developed
enables the identification of validated and putative
targets involved in the mesenchyme phenotype main-
tenance of triple negative breast cancer cells. These
targets need to be further investigated to demonstrate



























































Fig. 6 Pharmacological inhibition of DOT1L induces E-cadherin and CD24 expression in MDA-MB-231 in vitro. Cells were treated with dose effects
of EPZ-5676 (0.1 μM, 1 μM, 10 μM) or 0.1 % DMSO for the indicated days (noted d), followed by mRNA extraction and RT-qPCR with specific primers. a
E-CAD expression relative to non treated cells. b CD24 expression relative to non treated cells. Data in a and b are the mean of RT-qPCR replicates from
a representative experiment, and error bars indicate SEM. The experiments were run 2 times
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Additional file
Additional file 1: Raw Data. An excel file containing 10 spreadsheets.
Each spreadsheet has the name of the figure in which the data were
used. (XLS 788 kb)
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